SGLT2 Inhibitors May Slow Aging by Clearing Senescent Cells
Diabetes drugs like empagliflozin show surprising anti-aging effects β mimicking caloric restriction and reducing senescent cell burden.
20 articles
Diabetes drugs like empagliflozin show surprising anti-aging effects β mimicking caloric restriction and reducing senescent cell burden.
A landmark RCT shows finerenone reduces eGFR decline and kidney-cardiovascular events in CKD patients without diabetes.
New research shows phosphatidylserine supplementation reduces liver fat and inflammation while improving glucose control through enhanced fat metabolism.
Natural polyketide from marine bacteria enhances cholesterol removal and improves fat metabolism in liver cells and mice.
New study reveals how the diabetes drug dapagliflozin dramatically alters fat metabolism and kidney function through previously unknown pathways.
Updated review of anti-obesity medications in MASLD finds GLP-1 agonists reduce steatosis and fibrosis, while newer dual/triple agonists show even greater metabolic promise.
New research reveals semaglutide's liver benefits work independently of weight loss through specialized liver blood vessel cells.
Novel obesity drug targeting two pathways simultaneously shows unprecedented weight loss results in recent clinical studies.
Scientists discover how FGF21 fights liver disease through a key protein, opening new treatment paths for metabolic dysfunction.
50 nm polystyrene nanoplastics accumulate in mouse testes, degrading sperm quality and triggering iron-dependent cell death through a newly identified mitochondrial pathway.
Inclisiran safely reduced LDL cholesterol by 28% in adolescents with familial hypercholesterolemia, offering hope for early intervention.
Combining cold exposure with exercise activates a key metabolic pathway to reduce liver fat and fibrosis more effectively than either intervention alone.
Ketone body Ξ²-OHB prevents sepsis-induced liver damage by modifying antioxidant enzyme SOD2, offering new therapeutic approach.
New research reveals how the cholesterol medication bempedoic acid directly activates PPARΞ±, boosting fat metabolism beyond its known effects.
A systematic review of 8 studies finds tirzepatide significantly reduces hsCRP and IL-6 across all doses and populations.
New research reveals how SREBP2 protein triggers liver fibrosis through metabolic changes, offering hope for treating liver disease.
Flavo-Proxylane topical treatment plus ultrasound reduced skin laxity by 44% in people using weight loss medications.
Breakthrough study reveals sepiapterin dramatically outperforms existing PKU therapy, offering hope for better metabolic control.
A landmark JCI review maps the expanding pharmacological arsenal for MASH, from GLP-1 agonists to triple receptor therapies and precision medicine.
New research reveals how a key cellular protein prevents ferroptosis, a type of cell death implicated in aging and age-related diseases.